Furthermore, we explored whether mutant KRAS might impair the efficacy of adoptive cell‐transfer (ACT) therapy in CRC patient‐derived xenograft (PDX) models implanted in immunocompromised NOD.SCID mice (Figure 3E). Here, KRAS is linked to colorectal carcinoma.